...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Debt
7
Apr 02, 2022 01:01PM
4
Apr 03, 2022 09:50AM
4
Apr 03, 2022 12:26PM
2
Apr 03, 2022 01:04PM
3
Apr 03, 2022 03:47PM
4
Apr 03, 2022 04:08PM
1
Apr 03, 2022 04:30PM
6
Apr 03, 2022 04:55PM
2
Apr 04, 2022 09:48AM
5
Apr 04, 2022 10:29AM
2
Apr 04, 2022 10:39AM
4
Apr 04, 2022 03:10PM
7
Apr 05, 2022 08:47PM
4
Apr 06, 2022 07:43AM

,,,,,,,,,,,,,,,,,I still cant understand these big name Pharmas which are in trial with Zen and still are not making attempts to take it out,,,,,,,,,,,,,,,,,

I see no reason why they would do a buyout now.  Makes total sense they would want to see the results of those trials first.  Otherwise, why do a trial?  They need to determine if it works, how well, and safety, in order to know what it's worth.

Which means, IMO, we have to wait until one or more trials are done, plus many more months for results, plus many more months for them to ponder and negotiate a deal.

 

2
Apr 06, 2022 10:29AM
2
Apr 06, 2022 10:35AM
3
Apr 06, 2022 11:38AM
1
Apr 07, 2022 12:40PM
Share
New Message
Please login to post a reply